Following the innovation-driven development strategy, we continuouslyheighten the priority of technological innovation and advance research onmedicine for rare diseases. In the meantime, we keep a close eye on productquality and safety. In addition, we intensify collaborative efforts with otherenterprises to promote inclusive healthcare services, in a bid to deliver moreaccessible medical resources, communicate the health philosophy to the public,and eventually contribute to the development of this sector and to the HealthyChina Initiative.

n  Our Performance

l  In 2023,spending on scientific R&D RMB 852 million

l  In 2023, 90 scientific R&Dplatforms

l  In 2023, over 150ongoing project

l  In 2023, A high-level talent team is built, including 3 Nobel Prize winners, 1 Guangdong innovation team, 21 double-employed academicians and TCMmasters, 7 foreign expertconsultants, 1 foreign academicianfrom the Russian Academy of Engineering, 5experts enjoying special government allowance, 54 senior and above experts, and over 100 doctors and postdoctors.

l  In 2023, 134 patents applied,including 110 invention patentapplications and 24 utility modelpatent applications; 89 patentsauthorized , including 67 inventionpatens and 22 utility model patents

l  In 2023, 10 subsidiariescertified as Guangdong Specialized and Sophisticated SMEs, achieved 4 international awards and 10+ National, provincial andinstitutional technology awards

l  GYBYS won the title of 2023 BestIndustrial Enterprise for Pharmaceutical R&D Product Line in China

l  Baiyunshan General Factory’s “Cefprozil Combination”, and Xing Qun's “AMethod for Preparing Alfacalcidol Soft Capsules” won the 24th China Patent Excellence Awards

l  Zhong Yi’s “Innovative Research and Application of Zishenyutai Pill”project won the Gold Medal of the 48thInternational Exhibition of Inventions of Geneva in 2023

l  Wang Lao Ji’s “Quality Research and Industrial Application of WLJ HerbalTea” project won the Silver Medal ofInternational Exhibition of Inventions Geneva

n Our Approach to Access to Health Care

Powered by technological innovation, we make every effort to optimize ourinnovation resource allocation and shore up R&D capabilities on raredisease medicine. Our intellectual property management system is constantlyrefined to prevent relevant risks. We further enhance cooperation with partnersin a way of resource sharing and mutual learning to contribute more traditionalChinese medicine solutions for the Healthy China Initiative.

Product quality is the lifeline of an enterprise. We strictly abide bylaws and regulations on product quality and safety, and continuously improvelife-cycle quality management and our medicine warning system. Therefore we canguard against quality and safety risks, meet consumer requirements, and protecttheir legitimate rights and interests.

The pharmaceutical sector is foundational to people’s right to health.Committed to the idea of “an enterprise will get prosperous development whenbenefiting mankind with one heart”, we strive to facilitate the development ofhealthcare at primary level, carry forward TCM culture, and uphold equitablepricing, therefore benefiting people around the world with excellent TCM.

n Our Stories